- Home
- SI vs AMRN Comparison
SI vs AMRN Comparison
Compare SI & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$14.37
HOLD
Current Price
$15.53
Company Overview
Basic Information| Metric | SI | AMRN |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.3M | 339.8M |
| IPO Year | 2025 | 1993 |
Fundamental Metrics
Financial Performance| Metric | SI | AMRN |
|---|---|---|
| Price | $14.37 | $15.53 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 5 | 1 |
| Target Price | ★ $20.60 | $12.00 |
| AVG Volume (30 Days) | 40.6K | ★ 107.1K |
| Earning Date | 04-17-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $41,626,000.00 | ★ $226,733,000.00 |
| Revenue This Year | $48.42 | N/A |
| Revenue Next Year | $29.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 115.97 | N/A |
| 52 Week Low | $10.92 | $7.08 |
| 52 Week High | $17.94 | $20.90 |
Technical Indicators
Market Signals| Indicator | SI | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 54.82 |
| Support Level | $13.60 | $15.40 |
| Resistance Level | $15.25 | $17.31 |
| Average True Range (ATR) | 0.82 | 0.93 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 57.49 | 54.18 |
Price Performance
Historical Comparison SI
AMRN
About SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.